Apexus Advanced 340B Operations Practice Exam
Question 1: What is the primary purpose of the 340B Drug Pricing Program?
A. To increase drug prices for hospitals
B. To provide discounted drugs to eligible health care providers
C. To subsidize pharmaceutical companies
D. To fund private health insurance
Answer: B
Explanation: The program is designed to enable eligible health care providers to purchase
outpatient drugs at reduced prices, thereby supporting the provision of care to vulnerable
populations.
Question 2: Which entity is responsible for overseeing the compliance of the 340B
program?
A. Centers for Medicare & Medicaid Services
B. Food and Drug Administration
C. Health Resources and Services Administration
D. Drug Enforcement Administration
Answer: C
Explanation: HRSA is charged with administering and ensuring compliance with the 340B
program regulations.
Question 3: When was the 340B Drug Pricing Program originally established?
A. 1982
B. 1992
C. 1972
D. 2002
Answer: A
Explanation: The 340B program was established in 1992 to help safety-net providers expand
access to medications.
Question 4: Who are the primary beneficiaries of the 340B program?
A. Large pharmaceutical manufacturers
B. Private insurance companies
C. Eligible health care providers serving low-income populations
D. Retail pharmacies only
Answer: C
Explanation: Eligible health care providers, particularly those serving vulnerable and low-
income populations, benefit from the program by receiving discounted drugs.
Question 5: Which organization plays a pivotal role in managing the 340B program for
covered entities?
A. Centers for Disease Control and Prevention
,B. Apexus
C. National Institutes of Health
D. American Medical Association
Answer: B
Explanation: Apexus is the nonprofit organization responsible for administering the 340B
program and ensuring compliance among covered entities.
Question 6: What is one of the main goals of the 340B program?
A. To increase pharmaceutical profit margins
B. To support safety-net providers by reducing drug acquisition costs
C. To decrease patient access to specialty medications
D. To fund private research initiatives
Answer: B
Explanation: A major goal is to reduce drug acquisition costs for safety-net providers, allowing
them to reinvest savings into patient care.
Question 7: Which legislation governs the 340B Drug Pricing Program?
A. Affordable Care Act
B. Medicare Modernization Act
C. Public Health Service Act
D. Health Insurance Portability and Accountability Act
Answer: C
Explanation: The program is governed by the Public Health Service Act, which outlines its
structure and eligibility requirements.
Question 8: What role does Apexus play in the 340B program?
A. It manufactures drugs at discounted prices
B. It oversees program administration and compliance
C. It funds research for new drug development
D. It audits financial records for hospitals
Answer: B
Explanation: Apexus administers the program, ensuring that covered entities comply with
established guidelines and regulations.
Question 9: How does the 340B program help health care providers financially?
A. By offering grants for new equipment
B. By allowing them to purchase drugs at reduced prices
C. By subsidizing patient insurance premiums
D. By reducing staff salaries
Answer: B
Explanation: The program lowers the cost of drugs for eligible providers, allowing them to
allocate more resources to patient care.
Question 10: Which of the following best describes the evolution of the 340B program?
A. It has remained unchanged since inception
B. It has expanded to include more eligible entities and complex compliance measures
,C. It shifted focus to research and development funding
D. It primarily supports private hospitals exclusively
Answer: B
Explanation: Since its inception, the 340B program has evolved by expanding eligibility and
increasing oversight requirements to maintain program integrity.
Question 11: What is a key objective of the 340B program’s design?
A. Maximizing profits for pharmaceutical companies
B. Enhancing access to medications for underserved populations
C. Reducing the number of covered entities
D. Simplifying drug pricing for private insurers
Answer: B
Explanation: The program is designed to improve medication access for patients served by
safety-net providers through discounted drug pricing.
Question 12: Which stakeholder is primarily responsible for ensuring that drugs purchased
under the 340B program are used appropriately?
A. Pharmaceutical manufacturers
B. Covered entities
C. Contract pharmacies
D. Government regulators
Answer: B
Explanation: Covered entities must ensure that the drugs acquired through the program are
dispensed only to eligible patients, thereby maintaining program integrity.
Question 13: The 340B program primarily targets which area of health care?
A. Inpatient hospital services
B. Outpatient prescription drugs
C. Emergency medical services
D. Long-term care facilities
Answer: B
Explanation: The program is focused on outpatient prescription drugs, enabling covered entities
to lower their drug acquisition costs.
Question 14: What is a common challenge faced by stakeholders in the 340B program?
A. Excessive funding from the government
B. Complex compliance and auditing requirements
C. Overwhelming patient demand for drugs
D. A surplus of contract pharmacies
Answer: B
Explanation: The complex regulatory framework and rigorous auditing requirements are
common challenges for stakeholders in the 340B program.
Question 15: Which of the following best describes the intended impact of the 340B
program on patient care?
A. Increasing administrative burdens on providers
, B. Enhancing the quality and accessibility of care
C. Reducing the number of available medications
D. Lowering patient satisfaction scores
Answer: B
Explanation: By reducing drug costs, the program enables providers to invest more in patient
care and improve health outcomes.
Question 16: What role do pharmaceutical manufacturers play in the 340B program?
A. Setting higher drug prices
B. Providing drugs at discounted prices to eligible entities
C. Auditing covered entities
D. Determining patient eligibility
Answer: B
Explanation: Manufacturers are required to offer drugs at a discounted rate under the program to
support eligible health care providers.
Question 17: Which aspect of the 340B program requires strict adherence to prevent
diversion of medications?
A. Patient eligibility verification
B. Increasing drug profit margins
C. Expanding coverage to all providers
D. Reducing government oversight
Answer: A
Explanation: Verifying patient eligibility is crucial to ensure that only qualifying patients receive
discounted medications and to prevent diversion.
Question 18: What is one of the historical drivers behind the creation of the 340B
program?
A. The need for enhanced pharmaceutical research
B. The goal of improving access to medications for underserved populations
C. The requirement to subsidize insurance companies
D. The drive to privatize health care services
Answer: B
Explanation: The program was created to improve medication access for underserved and
vulnerable populations by offering discounted drug pricing.
Question 19: In the context of the 340B program, which term best describes a health care
provider that qualifies for participation?
A. Non-profit institution
B. Covered entity
C. Private practice
D. Retail chain
Answer: B
Explanation: Eligible health care providers that meet specific criteria under the program are
designated as “covered entities.”
Question 1: What is the primary purpose of the 340B Drug Pricing Program?
A. To increase drug prices for hospitals
B. To provide discounted drugs to eligible health care providers
C. To subsidize pharmaceutical companies
D. To fund private health insurance
Answer: B
Explanation: The program is designed to enable eligible health care providers to purchase
outpatient drugs at reduced prices, thereby supporting the provision of care to vulnerable
populations.
Question 2: Which entity is responsible for overseeing the compliance of the 340B
program?
A. Centers for Medicare & Medicaid Services
B. Food and Drug Administration
C. Health Resources and Services Administration
D. Drug Enforcement Administration
Answer: C
Explanation: HRSA is charged with administering and ensuring compliance with the 340B
program regulations.
Question 3: When was the 340B Drug Pricing Program originally established?
A. 1982
B. 1992
C. 1972
D. 2002
Answer: A
Explanation: The 340B program was established in 1992 to help safety-net providers expand
access to medications.
Question 4: Who are the primary beneficiaries of the 340B program?
A. Large pharmaceutical manufacturers
B. Private insurance companies
C. Eligible health care providers serving low-income populations
D. Retail pharmacies only
Answer: C
Explanation: Eligible health care providers, particularly those serving vulnerable and low-
income populations, benefit from the program by receiving discounted drugs.
Question 5: Which organization plays a pivotal role in managing the 340B program for
covered entities?
A. Centers for Disease Control and Prevention
,B. Apexus
C. National Institutes of Health
D. American Medical Association
Answer: B
Explanation: Apexus is the nonprofit organization responsible for administering the 340B
program and ensuring compliance among covered entities.
Question 6: What is one of the main goals of the 340B program?
A. To increase pharmaceutical profit margins
B. To support safety-net providers by reducing drug acquisition costs
C. To decrease patient access to specialty medications
D. To fund private research initiatives
Answer: B
Explanation: A major goal is to reduce drug acquisition costs for safety-net providers, allowing
them to reinvest savings into patient care.
Question 7: Which legislation governs the 340B Drug Pricing Program?
A. Affordable Care Act
B. Medicare Modernization Act
C. Public Health Service Act
D. Health Insurance Portability and Accountability Act
Answer: C
Explanation: The program is governed by the Public Health Service Act, which outlines its
structure and eligibility requirements.
Question 8: What role does Apexus play in the 340B program?
A. It manufactures drugs at discounted prices
B. It oversees program administration and compliance
C. It funds research for new drug development
D. It audits financial records for hospitals
Answer: B
Explanation: Apexus administers the program, ensuring that covered entities comply with
established guidelines and regulations.
Question 9: How does the 340B program help health care providers financially?
A. By offering grants for new equipment
B. By allowing them to purchase drugs at reduced prices
C. By subsidizing patient insurance premiums
D. By reducing staff salaries
Answer: B
Explanation: The program lowers the cost of drugs for eligible providers, allowing them to
allocate more resources to patient care.
Question 10: Which of the following best describes the evolution of the 340B program?
A. It has remained unchanged since inception
B. It has expanded to include more eligible entities and complex compliance measures
,C. It shifted focus to research and development funding
D. It primarily supports private hospitals exclusively
Answer: B
Explanation: Since its inception, the 340B program has evolved by expanding eligibility and
increasing oversight requirements to maintain program integrity.
Question 11: What is a key objective of the 340B program’s design?
A. Maximizing profits for pharmaceutical companies
B. Enhancing access to medications for underserved populations
C. Reducing the number of covered entities
D. Simplifying drug pricing for private insurers
Answer: B
Explanation: The program is designed to improve medication access for patients served by
safety-net providers through discounted drug pricing.
Question 12: Which stakeholder is primarily responsible for ensuring that drugs purchased
under the 340B program are used appropriately?
A. Pharmaceutical manufacturers
B. Covered entities
C. Contract pharmacies
D. Government regulators
Answer: B
Explanation: Covered entities must ensure that the drugs acquired through the program are
dispensed only to eligible patients, thereby maintaining program integrity.
Question 13: The 340B program primarily targets which area of health care?
A. Inpatient hospital services
B. Outpatient prescription drugs
C. Emergency medical services
D. Long-term care facilities
Answer: B
Explanation: The program is focused on outpatient prescription drugs, enabling covered entities
to lower their drug acquisition costs.
Question 14: What is a common challenge faced by stakeholders in the 340B program?
A. Excessive funding from the government
B. Complex compliance and auditing requirements
C. Overwhelming patient demand for drugs
D. A surplus of contract pharmacies
Answer: B
Explanation: The complex regulatory framework and rigorous auditing requirements are
common challenges for stakeholders in the 340B program.
Question 15: Which of the following best describes the intended impact of the 340B
program on patient care?
A. Increasing administrative burdens on providers
, B. Enhancing the quality and accessibility of care
C. Reducing the number of available medications
D. Lowering patient satisfaction scores
Answer: B
Explanation: By reducing drug costs, the program enables providers to invest more in patient
care and improve health outcomes.
Question 16: What role do pharmaceutical manufacturers play in the 340B program?
A. Setting higher drug prices
B. Providing drugs at discounted prices to eligible entities
C. Auditing covered entities
D. Determining patient eligibility
Answer: B
Explanation: Manufacturers are required to offer drugs at a discounted rate under the program to
support eligible health care providers.
Question 17: Which aspect of the 340B program requires strict adherence to prevent
diversion of medications?
A. Patient eligibility verification
B. Increasing drug profit margins
C. Expanding coverage to all providers
D. Reducing government oversight
Answer: A
Explanation: Verifying patient eligibility is crucial to ensure that only qualifying patients receive
discounted medications and to prevent diversion.
Question 18: What is one of the historical drivers behind the creation of the 340B
program?
A. The need for enhanced pharmaceutical research
B. The goal of improving access to medications for underserved populations
C. The requirement to subsidize insurance companies
D. The drive to privatize health care services
Answer: B
Explanation: The program was created to improve medication access for underserved and
vulnerable populations by offering discounted drug pricing.
Question 19: In the context of the 340B program, which term best describes a health care
provider that qualifies for participation?
A. Non-profit institution
B. Covered entity
C. Private practice
D. Retail chain
Answer: B
Explanation: Eligible health care providers that meet specific criteria under the program are
designated as “covered entities.”
